Head of Strategy at the Longevity Biotech Fellowship and founder of Coenzyme. I advise life science and longevity biotech organisations on commercial strategy, fundraising, M&A, and operational planning.

Cambridge-trained in natural sciences, grounded in corporate finance through the ACA and a background in M&A advisory. I translate technical depth into clear narratives, investable plans, and roadmaps teams can execute.

I'd never profess to have all the answers - I do think we can find the right path to reach them.

Longevity research is one of the best levers we have for reducing human suffering at scale. Few fields offer that kind of upside.

In short, I think people dying is bad.

Investors and governments have been oddly myopic. At COVID's peak, a single year of research spending exceeded everything ever put into serious longevity work across modern medicine.

It's a moral imperative to give people informed ways to engage with what's happening at the frontier - not kept at arm's length by lack of clarity, hype, or bad comms.